Medical news
-
Gene therapy in hemophilia a hot topic at the WFH Global Forum 2019
Gene therapy in hemophilia featured heavily at the World Federation of Hemophilia Global Forum held in Montréal November 13 to 14, 2019. Glenn Pierce, MD,...
-
Now available: The WFH Report on the Annual Global Survey 2018
The World Federation of Hemophilia (WFH) Report on the Annual Global Survey (AGS) 2018 is now available! This survey provides a global snapshot of the...
-
WFH holds webinar titled Updated Estimates of Prevalence and Prevalence at Birth of Hemophilia
The World Federation of Hemophilia (WFH) has spearheaded a scientific study updating the prevalence of hemophilia to higher numbers than previously estimated and providing, for...
-
A WFH Advisory on Particulate Matter in Emicizumab (HEMLIBRA) and Other Biologic Agents
Since the development of intravenous therapies, the presence of particulate matter in injectable drugs has been a concern for clinicians. While some particles can come...
-
WFH has spearheaded a scientific study updating the prevalence of hemophilia to higher numbers than previously estimated
The World Federation of Hemophilia (WFH) has spearheaded a scientific study updating the prevalence of hemophilia to higher numbers than previously estimated and providing, for...
-
Hurry! Earn CME credits with the gene therapy clinical education program
Enhance your knowledge of emerging gene therapy in hemophilia and claim up to 1.75 AMA PRA Category 1 Credits™ in 2019 with Clinical Advances in...
-
Recommendation on the use of Cryoprecipitate
The Medical Advisory Board of the WFH has published recommendation on the use of Cryoprecipitate for Treatment of Congenital Bleeding Disorders, on 26 April 2019. The recommendations are as follows:...
-
1st WBDR Data Report to be released soon
The WFH is proud to announce that the 1st World Bleeding Disorders Registry (WBDR) Data Report will be published this summer. The WBDR Data Report...
-
Novo Nordisk announces FDA approves the Biologics License Application for ESPEROCT®
Novo Nordisk announces that the US Food and Drug Administration (FDA) has approved the Biologics License Application for turoctocog alfa pegol, N8-GP, (ESPEROCT)®, a recombinant extended half-life...
-
WFH publication explores challenges and opportunities of gene therapy
In the first of a series of round table meetings, the World Federation of Hemophilia (WFH) Gene Therapy Round Table was convened in April 2018...
